NLTX - Neoleukin Therapeutics GAAP EPS of -$0.24 beats by $0.07
- Neoleukin Therapeutics press release ( NASDAQ: NLTX ): Q3 GAAP EPS of -$0.24 beats by $0.07 .
- Cash, cash equivalents, and short-term investments totaled $106.9 million as of September 30, 2022, compared to $142.5 million as of December 31, 2021.
For further details see:
Neoleukin Therapeutics GAAP EPS of -$0.24 beats by $0.07